Immunology & inflammation

Uveitis is a small but sticky indication where a non-steroid oral option is valued, and another label extension spreads development cost across more indications. The market will want to see the effect size against the standard of care, not just the win itself. I'd expect this to feed straight into Roivant's partnering and financing narrative for the asset.

An oral α4β7 blocker is the obvious answer to injectable vedolizumab, and a roughly 23-point placebo-adjusted remission is credible for a Phase 2. But the p-values are nominal and the arms are small, so Phase 3 and Takeda's entrenched biologic franchise, not this readout, decide whether the oral convenience story pays.

Early healthy-volunteer data showing a deep IgE drop give the story a clinical anchor, and an IPO is a useful test of public-market appetite for degraders outside oncology. The competition is formidable, though: omalizumab and its successors already own IgE, so Lycia must show a durable, differentiated edge.

The $7.8B headline is mostly contingent; the $575M upfront is the real conviction signal. Landing this after pausing an autoimmune CAR-T program reads like Novartis hedging its B-cell reset thesis toward an in vivo, mRNA-delivered CD19xCD3 format. The options on other Abogen RNA programs suggest it is buying platform access, not just one asset.

This is Sanofi buying a Dupixent successor from the one partner that already knows how to make that franchise work, ahead of the 2031 US patent expiry. Paying $1B for a Phase 1 antibody and three preclinical ones is really a bet on long-acting dosing as the differentiator against a crowded type 2 inflammation field. For Regeneron it is non-dilutive funding plus a reconfirmed partner; I'd watch whether Sanofi's other immunology assets get de-prioritized.

BMS ceding Japan commercial lead to Maruho is a tacit admission that dermatologist relationships beat global scale here — the classic foreign-innovator/domestic-specialist access play. Adding rheumatology promotion right after the May PsA nod signals urgency to outrun oral JAK rivals before positioning hardens. For Maruho, it's low-risk topline padding that fits its derm book without R&D exposure.

Complement factor B suppression becomes a third distinct mechanism validated in IgA nephropathy, joining sparsentan's endothelin/AT1 blockade and the B-cell/APRIL plays from atacicept and sibeprenlimab; convergent proteinuria data across mechanisms suggests the market fragments by dosing convenience, not efficacy. Once-monthly self-injection undercuts daily oral and infused rivals on adherence, while Ionis banks another platform-licensing win validating its originate-and-out-license model.

No imbalance in blood clots or infections is the headline that matters most: CD40L antagonists carry a long history of thromboembolic failures, so this clean safety data de-risks the whole mechanism, not just Amgen's asset. It also finally validates the $27.8B Horizon buy, giving Amgen the first credible disease-modifying candidate in a zero-approved-therapy indication—with a second Phase 3 in a milder segment positioning it to own both ends of the severity spectrum.

Fourth China-sourced discovery deal for Lilly since early 2025 — this is deliberate strategy, not opportunism: outsourcing early-target risk to lower-cost Chinese biotech engines. The $100M upfront against $3.35B total (~3%) is a cheap option on unproven targets, not a derisked buy. China's shifting from manufacturing base to discovery pipeline for Big Pharma.

The reverse-merger-plus-PIPE playbook is becoming the default exit ramp for well-capitalized private biotechs in a still-tepid IPO market — expect more of these Nasdaq-shell conversions through 2026 as sponsors sidestep the pricing risk of a traditional roadshow. More interesting is the origin story: ADAR1 Capital incubating NOR-101 in-house for two years before spinning it out is a hedge fund acting like a venture creator, not just a stock-picker — a build-then-monetize model worth watching as more crossover funds chase asset-level returns. Going after IL-13/IL-18 dual blockade puts North squarely in Dupixent's shadow; differentiated mechanism aside, atopic dermatitis is already crowded (Amgen's rocatinlimab, Sanofi/Regeneron's own follow-ons), so competitive execution and pricing power at launch will matter more than novelty. With Phase 1a not starting until 2027, there's no near-term catalyst — this is a story investors have to hold through, not trade around.

Tepezza is a multi-billion-dollar franchise that helped justify Amgen's $27.8B Horizon Therapeutics acquisition — so an oral challenger here isn't just chasing an indication, it's chasing the economics that made that deal work. Forbion leading a $123M round through Phase 3, with TPG re-upping and Sectoral joining fresh, signals real conviction in the differentiation thesis itself, not just TED as a hot category. The commercial logic is straightforward: IV infusions carry site-of-care burden, scheduling friction, and infusion-reaction risk that a pill sidesteps — real value in a chronic, relapsing disease where compliance matters. But incumbents hold prescriber relationships and entrenched reimbursement pathways; an oral entrant more likely peels off infusion-averse or relapsed patients first than displaces frontline share outright, unless Phase 3 data show a decisive edge.

Tepezza turned thyroid eye disease into a blockbuster franchise despite being an IV-infused biologic — an oral IGF-1R inhibitor now running its own Phase 3 is the first mechanism-matched threat with real clinical data behind it, and Amgen should take notice. The deal's backstory is arguably the sharper story: an Astellas oncology asset shelved, licensed out in 2022, and repositioned for ophthalmology now sits in pivotal testing — the underappreciated-asset playbook every BD team wants to replicate. A $123M Series C landing at Phase 3, not an earlier round, with Forbion leading and new crossover-style investor Sectoral joining incumbent TPG, reads as genuine conviction, not speculative money chasing a hot indication. TED is a small, rare-disease market, but Tepezza proved payers and patients will pay for relief — an oral, self-administered option could expand that funnel further if the proptosis data holds up at 24 weeks.

Confirmatory data this clean removes the single biggest overhang on TRUTAKNA's commercial story: accelerated approvals routinely get pulled or delayed when post-marketing trials disappoint, and Vera now walks into its Q4 sBLA filing with full-approval leverage rather than hope. That matters in a field crowding fast — Travere's Filspari, Calliditas/Otsuka's Tarpeyo, Novartis's Fabhalta, and Otsuka's sibeprenlimab are all fighting for the same nephrologists. Atacicept's dual APRIL/BAFF mechanism gives Vera a real differentiation story on upstream disease modification, not just symptom control, which should support pricing and payer positioning as uptake scales. For a company Vera's size, a de-risked full approval also reshapes M&A calculus — this is now a cleaner acquisition target for a larger nephrology or immunology player looking to buy share rather than build it.

Full, hierarchically-tested endpoint clearance across proteinuria, Gd-IgA1, and hematuria is exactly the kind of data package payers and prescribers weight most heavily when a drug's approval is still accelerated and provisional — this reads as Vera's strongest case yet for converting TRUTAKNA to full approval and retiring the confirmatory-trial overhang that's been sitting on the stock. That matters disproportionately for a single-asset company: Vera has no second program to fall back on if ORIGIN 3 had disappointed, so a clean conversion is existential, not incremental. It also sharpens the IgAN scramble — Travere's sparsentan (Filspari), Novartis's atrasentan (Vanrafia), and Otsuka's entrants are all fighting for first-line real estate in a field that's gone from orphan afterthought to genuinely contested in under two years. Durable, un-caveated data is now the differentiator, not novelty of mechanism alone.